Home > Neurology > EAN 2019 > Parkinson's Disease and other Movement Disorders > Epigallocatechin gallate does not modify MSA progression

Epigallocatechin gallate does not modify MSA progression

Presented By
Dr Johannes Levin, Ludwig-Maximilians-University of Munich, Germany
Conference
EAN 2019
Trial
PROMESA
In the placebo controlled PROMESA trial, epigallocatechin gallate (EGCG) did not modify disease progression in patients with multiple system atrophy (MSA). EGCG, found in low levels in green tea, was well-tolerated. The hepatotoxic effects observed in some patients limit dosing, however [1]. These results where shared as a late-breaking abstract at the EAN 2019 and simultaneously published [2]. First author Dr Johannes Levin (Ludwig-Maximilians-University of Munich, Germany) explained that the polyphenol EGCG inhibits α-synuclein aggregation in higher doses. A dozen specialist centres in Germany participated in the trial. In total, 92 participants were randomly assigned to oral EGCG 400 mg or matching placebo once daily for 4 weeks, then twice daily for 4 weeks, followed by three times daily for 40 weeks; 63 patients completed the study per protocol. After 52 weeks, there was no difference in change from baseline in motor examination scores on the U...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on